博川报道：一个网络医疗研究机构的科学家将在美国各地开始一系列的临床试验,以收集流感疫苗关键数据,其中包括两个候选H1N1禽流感疫苗.这项研究将在国家过敏和传染病研究院（ NIAID）的指导下进行,这个研究院是美国国立卫生研究分院.
   “针对2009年H1N1流感病毒的出现,我们已经逐步开展了高效协作的疫苗开发研究工作.”美国NIAID的主任安东尼福西博士说.在分离和鉴定了H1N1 病毒,美国疾控和预防中心分离并分发了2009 H1N1种子病毒样本给疫苗制造商,用于疫苗开发的临床试验.
   “现在,将使用我们的长期疫苗临床试验基础设施---疫苗和治疗评价单位---以帮助快速评估这些实验来确定这些疫苗是否安全,并评估其诱导保护性免疫反应的能力,”博士说福奇. “这些数据将成为做出如何及是否执行今年秋天2009 H1N1流感病毒免疫上市这个决定的参考.”
 (博川  fish)

博川推荐原文检索：
【Abstract】
  NIAID Set to Launch Clinical Trials to Test
  2009 H1N1 Influenza Vaccine Candidates
  Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines. The research will be under the direction of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
  “With the emergence of the 2009 H1N1 influenza virus, we have undertaken a collaborative and efficient process of vaccine development that is proceeding in stepwise fashion,” says NIAID Director Anthony S. Fauci, M.D.
   After the isolation and characterization of the virus, the U. S. Centers for Disease Control and Prevention generated and distributed a 2009 H1N1 seed virus to vaccine manufacturers for the development of vaccine pilot lots for testing in clinical trials.
  “Now, NIAID will use our longstanding vaccine clinical trials infrastructure—the Vaccine and Treatment Evaluation Units—to help quickly evaluate these pilot lots to determine whether the vaccines are safe and to assess their ability to induce protective immune responses,” says Dr. Fauci. “These data will be factored into the decision about how and if to implement a 2009 H1N1 flu immunization program this fall.”
  原文链接"A key step for the future will be to identify the cellular pathways that are affected by these cyclic peptide原:
http://www3.niaid.nih.gov/news/newsreleases/2009/VTEU_H1N1.htm

相关阅读
至今甲型H1N1流感至少造成18156人死亡
甲型H1N1流感病毒外形为杆状而非球状
甲型H1N1流感病毒基因分析结果